α-Glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro

Soichiro Ishihara, Mie Nieda, Joji Kitayama, Takuya Osada, Toshio Yabe, Akiko Kikuchi, Yasuhiko Koezuka, Steven A. Porcelli, Kenji Tadokoro, Hirokazu Nagawa, Takeo Juji

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

α-Glycosylceramides, such as α-galactosylceramide and α- glucosylceramide, induce antitumor immunity in various murine cancer models. In the murine hepatic metastasis model, Vα14 TCR+NK1.1+ T cells, which accumulate preferentially in the liver, are considered to play a key role in the induction of antitumor immunity by α-glycosylceramides. We recently reported that Vα24 TCR+ NKT cells, the human homologues of murine Vα14 TCR+NK1.1+ cells, are rarely seen among freshly isolated human hepatic lymphocytes. Therefore, it is important to examine whether α- glycosylceramides also enhance the antitumor cytotoxicity of human hepatic lymphocytes, as they have been shown to do in murine systems, to determine the usefulness of α-glycosylceramides in cancer immunotherapy in humans. Here, we show that α-glycosylceramides greatly enhance the cytotoxicity of human hepatic lymphocytes obtained from cancer patients against the tumor cell lines, K562 and Colo201, in vitro. The direct effector cells of the elicited cytotoxicity were CD3-CD56+ NK cells. Even though Vα24 TCR-NKT cells proliferated remarkably in response to α-glycosylceramides, they did not contribute directly to the cytotoxicity. Our observations strongly suggest the potential usefulness of α-glycosylceramides for immunotherapy of liver cancer in humans based on their ability to activate CD3-CD56+NK cells in the liver.

Original languageEnglish (US)
Pages (from-to)1659-1664
Number of pages6
JournalJournal of Immunology
Volume165
Issue number3
StatePublished - Aug 1 2000

Fingerprint

Natural Killer Cells
Lymphocytes
Liver
Neoplasms
Natural Killer T-Cells
Immunotherapy
Immunity
Galactosylceramides
Glucosylceramides
Liver Neoplasms
Tumor Cell Line
In Vitro Techniques
Neoplasm Metastasis
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology

Cite this

Ishihara, S., Nieda, M., Kitayama, J., Osada, T., Yabe, T., Kikuchi, A., ... Juji, T. (2000). α-Glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro. Journal of Immunology, 165(3), 1659-1664.

α-Glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro. / Ishihara, Soichiro; Nieda, Mie; Kitayama, Joji; Osada, Takuya; Yabe, Toshio; Kikuchi, Akiko; Koezuka, Yasuhiko; Porcelli, Steven A.; Tadokoro, Kenji; Nagawa, Hirokazu; Juji, Takeo.

In: Journal of Immunology, Vol. 165, No. 3, 01.08.2000, p. 1659-1664.

Research output: Contribution to journalArticle

Ishihara, S, Nieda, M, Kitayama, J, Osada, T, Yabe, T, Kikuchi, A, Koezuka, Y, Porcelli, SA, Tadokoro, K, Nagawa, H & Juji, T 2000, 'α-Glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro', Journal of Immunology, vol. 165, no. 3, pp. 1659-1664.
Ishihara, Soichiro ; Nieda, Mie ; Kitayama, Joji ; Osada, Takuya ; Yabe, Toshio ; Kikuchi, Akiko ; Koezuka, Yasuhiko ; Porcelli, Steven A. ; Tadokoro, Kenji ; Nagawa, Hirokazu ; Juji, Takeo. / α-Glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro. In: Journal of Immunology. 2000 ; Vol. 165, No. 3. pp. 1659-1664.
@article{5034882749c449288b01a4d4306f03b0,
title = "α-Glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro",
abstract = "α-Glycosylceramides, such as α-galactosylceramide and α- glucosylceramide, induce antitumor immunity in various murine cancer models. In the murine hepatic metastasis model, Vα14 TCR+NK1.1+ T cells, which accumulate preferentially in the liver, are considered to play a key role in the induction of antitumor immunity by α-glycosylceramides. We recently reported that Vα24 TCR+ NKT cells, the human homologues of murine Vα14 TCR+NK1.1+ cells, are rarely seen among freshly isolated human hepatic lymphocytes. Therefore, it is important to examine whether α- glycosylceramides also enhance the antitumor cytotoxicity of human hepatic lymphocytes, as they have been shown to do in murine systems, to determine the usefulness of α-glycosylceramides in cancer immunotherapy in humans. Here, we show that α-glycosylceramides greatly enhance the cytotoxicity of human hepatic lymphocytes obtained from cancer patients against the tumor cell lines, K562 and Colo201, in vitro. The direct effector cells of the elicited cytotoxicity were CD3-CD56+ NK cells. Even though Vα24 TCR-NKT cells proliferated remarkably in response to α-glycosylceramides, they did not contribute directly to the cytotoxicity. Our observations strongly suggest the potential usefulness of α-glycosylceramides for immunotherapy of liver cancer in humans based on their ability to activate CD3-CD56+NK cells in the liver.",
author = "Soichiro Ishihara and Mie Nieda and Joji Kitayama and Takuya Osada and Toshio Yabe and Akiko Kikuchi and Yasuhiko Koezuka and Porcelli, {Steven A.} and Kenji Tadokoro and Hirokazu Nagawa and Takeo Juji",
year = "2000",
month = "8",
day = "1",
language = "English (US)",
volume = "165",
pages = "1659--1664",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - α-Glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro

AU - Ishihara, Soichiro

AU - Nieda, Mie

AU - Kitayama, Joji

AU - Osada, Takuya

AU - Yabe, Toshio

AU - Kikuchi, Akiko

AU - Koezuka, Yasuhiko

AU - Porcelli, Steven A.

AU - Tadokoro, Kenji

AU - Nagawa, Hirokazu

AU - Juji, Takeo

PY - 2000/8/1

Y1 - 2000/8/1

N2 - α-Glycosylceramides, such as α-galactosylceramide and α- glucosylceramide, induce antitumor immunity in various murine cancer models. In the murine hepatic metastasis model, Vα14 TCR+NK1.1+ T cells, which accumulate preferentially in the liver, are considered to play a key role in the induction of antitumor immunity by α-glycosylceramides. We recently reported that Vα24 TCR+ NKT cells, the human homologues of murine Vα14 TCR+NK1.1+ cells, are rarely seen among freshly isolated human hepatic lymphocytes. Therefore, it is important to examine whether α- glycosylceramides also enhance the antitumor cytotoxicity of human hepatic lymphocytes, as they have been shown to do in murine systems, to determine the usefulness of α-glycosylceramides in cancer immunotherapy in humans. Here, we show that α-glycosylceramides greatly enhance the cytotoxicity of human hepatic lymphocytes obtained from cancer patients against the tumor cell lines, K562 and Colo201, in vitro. The direct effector cells of the elicited cytotoxicity were CD3-CD56+ NK cells. Even though Vα24 TCR-NKT cells proliferated remarkably in response to α-glycosylceramides, they did not contribute directly to the cytotoxicity. Our observations strongly suggest the potential usefulness of α-glycosylceramides for immunotherapy of liver cancer in humans based on their ability to activate CD3-CD56+NK cells in the liver.

AB - α-Glycosylceramides, such as α-galactosylceramide and α- glucosylceramide, induce antitumor immunity in various murine cancer models. In the murine hepatic metastasis model, Vα14 TCR+NK1.1+ T cells, which accumulate preferentially in the liver, are considered to play a key role in the induction of antitumor immunity by α-glycosylceramides. We recently reported that Vα24 TCR+ NKT cells, the human homologues of murine Vα14 TCR+NK1.1+ cells, are rarely seen among freshly isolated human hepatic lymphocytes. Therefore, it is important to examine whether α- glycosylceramides also enhance the antitumor cytotoxicity of human hepatic lymphocytes, as they have been shown to do in murine systems, to determine the usefulness of α-glycosylceramides in cancer immunotherapy in humans. Here, we show that α-glycosylceramides greatly enhance the cytotoxicity of human hepatic lymphocytes obtained from cancer patients against the tumor cell lines, K562 and Colo201, in vitro. The direct effector cells of the elicited cytotoxicity were CD3-CD56+ NK cells. Even though Vα24 TCR-NKT cells proliferated remarkably in response to α-glycosylceramides, they did not contribute directly to the cytotoxicity. Our observations strongly suggest the potential usefulness of α-glycosylceramides for immunotherapy of liver cancer in humans based on their ability to activate CD3-CD56+NK cells in the liver.

UR - http://www.scopus.com/inward/record.url?scp=0034254423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034254423&partnerID=8YFLogxK

M3 - Article

C2 - 10903777

AN - SCOPUS:0034254423

VL - 165

SP - 1659

EP - 1664

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -